Elevated Ambulatory Blood Pressure Measurements are Associated with a Progressive Form of Fabry Disease.
Anderson–Fabry disease
Blood pressure monitoring
Hypertension
Lysosomal storage disorder
Masked hypertension
Journal
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
ISSN: 1179-1985
Titre abrégé: High Blood Press Cardiovasc Prev
Pays: New Zealand
ID NLM: 9421087
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
21
01
2021
accepted:
30
03
2021
pubmed:
13
4
2021
medline:
25
6
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
INTRODUCTION: Published data on hypertension incidence and management in Anderson-Fabry disease are scant and the contribution of elevated blood pressure to organ damage is not well recognized. Therefore, we have assessed blood pressure values and their possible correlations with clinical findings in a well described cohort of Fabry patients. Between January 2015 and May 2019, all adult Fabry patients (n = 24 females, n = 8 males) referred to our institute were prospectively enrolled. During the first examination patient's genotype and clinical characteristics were recorded. Blood pressure data were obtained by standard observed office measurements followed, within 6 months, by ambulatory blood pressure monitoring and home self-recordings. Organ involvement, including kidneys, heart and brain, was monitored over time. Consequently, patients were defined as clinically stable or progressive through the Fabry Stabilization Index. The standard office measurements have diagnosed hypertension in three (9.37%) patients, but the ambulatory monitoring showed elevated blood pressure in six (18.75%) patients, revealing three cases of masked hypertension. All the hypertensive patients were females and, compared with normotensive subjects, they presented a lower glomerular filtration rate (p < 0.05) and a more advanced cardiac hypertrophy (p < 0.05). Four (66.7%) of them were diagnosed with a progressive form of the disease through the Fabry Stabilization Index while the majority of the normotensive group (84.6%, n = 19) was stable over time. No correlation was found between the prevalence of hypertension and the type of mutations causing Fabry disease. Hypertension can be found in a restricted portion of clinically stable Fabry patients. In contrast, patients presenting with a progressive organ involvement, particularly renal impairment, have a major risk of developing uncontrolled blood pressure, and should be followed carefully. Moreover, the ambulatory blood pressure monitoring proved to be useful to reveal masked hypertension, which can contribute to the progressive worsening of the organ damage. Therefore, a proper diagnosis and therapy of hypertension may improve the outcome of Fabry patients.
Identifiants
pubmed: 33844184
doi: 10.1007/s40292-021-00450-0
pii: 10.1007/s40292-021-00450-0
pmc: PMC8087548
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-319Références
Mol Genet Genomic Med. 2018 Apr 12;:
pubmed: 29649853
J Am Soc Nephrol. 2002 Jun;13 Suppl 2:S134-8
pubmed: 12068025
Adv Chronic Kidney Dis. 2015 Mar;22(2):116-22
pubmed: 25704348
Nephrol Dial Transplant. 2008 May;23(5):1600-7
pubmed: 18175781
Orphanet J Rare Dis. 2010 Nov 22;5:30
pubmed: 21092187
J Med Genet. 2014 Jan;51(1):1-9
pubmed: 23922385
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
J Cell Biochem. 2001;82(4):674-82
pubmed: 11500945
Am J Hypertens. 2006 Aug;19(8):782-7
pubmed: 16876675
Mol Genet Metab. 2017 Aug;121(4):320-324
pubmed: 28663131
Medicine (Baltimore). 2002 Mar;81(2):122-38
pubmed: 11889412
Int J Cardiol. 2013 Sep 10;167(6):2555-60
pubmed: 22805550
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2812-7
pubmed: 18287059
Orphanet J Rare Dis. 2009 Oct 11;4:21
pubmed: 19818152
Mol Genet Metab. 2017 Nov;122(3):19-27
pubmed: 28947349
Ethn Dis. 2016 Jul 21;26(3):279-84
pubmed: 27440966
Nephrol Dial Transplant. 2009 Jul;24(7):2102-11
pubmed: 19218538
J Hypertens. 1997 Sep;15(9):995-1000
pubmed: 9321747
Mol Genet Metab Rep. 2020 Feb 15;22:100565
pubmed: 32099817
BMC Nephrol. 2013 Jan 11;14:6
pubmed: 23305247
J Clin Hypertens (Greenwich). 2016 Jun;18(6):551-6
pubmed: 26459236
Clin J Am Soc Nephrol. 2020 Apr 7;15(4):569-576
pubmed: 32132142
Curr Opin Nephrol Hypertens. 2005 Mar;14(2):87-95
pubmed: 15687833
Medicine (Baltimore). 2019 Jul;98(28):e16256
pubmed: 31305407
Mol Genet Metab. 2010 Feb;99(2):99-108
pubmed: 19900828
Clin Nephrol. 2018 Sep;90(3):227-231
pubmed: 29792392
Nephron Clin Pract. 2011;118(1):c43-8
pubmed: 21071972
Clin Kidney J. 2016 Oct;9(5):739-47
pubmed: 27679722
Dtsch Arztebl Int. 2010 Dec;107(49):866-73
pubmed: 21191547
Clin J Am Soc Nephrol. 2020 Apr 7;15(4):501-510
pubmed: 32217635
J Hypertens. 2018 Dec;36(12):2284-2309
pubmed: 30379783
J Pharmacol Sci. 2012;120(2):77-88
pubmed: 23079502
J Res Med Sci. 2014 Apr;19(4):358-67
pubmed: 25097610
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Clin J Am Soc Nephrol. 2020 Apr 7;15(4):441-443
pubmed: 32217636
Ann Neurol. 2000 Feb;47(2):229-33
pubmed: 10665494
Clin Nephrol. 2005 May;63(5):394-401
pubmed: 15909601